BCG003 is a fully human monoclonal antibody targeting TNFR2, which was co-developed by Biocytogen and Dragon Boat Pharmaceutical. The preclinical results showed that BCG003 is an agonistic TNFR2 antibody without blocking the TNFα-TNFR2 interactions. BCG003 has a favorable anti-tumor activity in many syngeneic mouse tumor models. In addition, BCG003 can enhance the anti-tumor activity of immune checkpoint blockades in TNFR2 humanized mice with good safety profile.
Figure 1. BCG003 showed anti-tumor activity in multiple tumor models.
2. Treatment of BCG003 enhanced the efficacy of PD-1/PD-L1 blockade in MC38 model
3. BCG003 is an IgG1 antibody with ADCC activity. In addition, BCG003 can enhance the CD8+ T cell proliferation. In vitro experiment showed that BCG003 treatment significantly increased the Teff/Treg ratio in tumor-microenvironment.
AACR2023: 1C3, A Novel Non-Blocking Anti-Human TNFR2 Antibody, Promotes Effector T Cell Responses and Demonstrates Potent Anti-Tumor Activity
AACR2022: 1C3, a Novel non-blocking anti-human TNFR2 antibody generated from RenMice, exhibits promising anti-tumor activity and safety in syngeneic tumor models in humanized TNFR2 mice